Biovica is uniquely positioned to address one of the major challenges in cancer therapy today; how to better evaluate therapeutic efficacy and improve quality of life in patients with advanced stages of the disease.
A simple blood sample
DiviTum™ is an innovative biomarker assay developed with the aim to monitor and predict treatment response in cancer therapy. It offers several advantages over alternative techniques that are standard in advanced breast cancer. In several clinical trials, the DiviTum™ biomarker assay has demonstrated the potential to quickly evaluate treatment effect and accurately predict outcome using just a simple blood sample.
New unique data from US breast cancer congress
The results demonstrate that palbociclib significantly reduced serum TK-activity levels in patients with hormone sensitive, HER2- breast cancer already after 2 weeks of treatment. DiviTum™ measured changes in serum TK-activity that was significantly correlated to the tumor Ki67 proliferation index. DiviTum™ may thus serve as a non-invasive marker and early response indicator of the anti-tumor effect of CDK4/6 inhibitors like palbociclib.
Biovica, a Swedish biotech company founded in 2009, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome. Biovica is supported by The European Commission and has been selected to receive funding in the Horizon 2020 phase 2 program.
Uppsala, Sweden, May 22 2017. Samuel Rotstein has been appointed as Scientific Advisor to Biovica.
Uppsala, Sweden May 9 2017. Biovica has received a new patent in China as well as patent extension for the company's technology in the United States. Both of the patents refer to Biovica's method of measuring thymidine kinase activity on [...]
Uppsala, Sweden, May 4 2017. Biovica has received an order for the company's product DiviTum® from a global contract research company (CRO company), commissioned by a global pharmaceutical company to study the effectiveness of new cancer drugs.
from day one
Breast cancer is the most common form of cancer among women today, affecting approximately 362,000 individuals in the EU and 233,000 in the US each year. Better tests for evaluating therapeutic efficacy, such as Biovica’s DiviTum™ biomarker assay, aim to increase survival and improve quality of life.
Clinical trials and Collaborations
Biovica has successfully worked to realize its vision for Divitum™ by initiating collaborations with globally-renowned research institutes such as the Karolinska Institute and the Dana Farber Cancer institute, as well as the International Breast Cancer Study Group (IBCSG) and the Breast International Group (BIG).